TGA
Following a public consultation process between 24 November 2025 - 10 February 2026, the TGA has adopted the following 23 international scientific guidelines:
- ICH guideline S1 Regulatory notice on changes to core guideline on rodent carcinogenicity testing of pharmaceuticals
- Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)
- Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations IV: Paediatric population
- ICH guideline Q9 (R1) on quality risk management
- Guideline on quality of herbal medicinal products/traditional herbal medicinal products - Final
- Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 2
- Guideline on the investigation of subgroups in confirmatory clinical trials
- Ezetimibe tablet 10 mg product-specific bioequivalence guidance
- Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products - Guidance for Industry
- Gefitinib film-coated tablet 250 mg product-specific bioequivalence guidance
- Guideline on adjuvants in vaccines for human use
- Guideline on clinical evaluation of vaccines
- Guideline on Stability Testing: Stability testing of existing active substances and related finished products
- ICH Q2(R2) guideline on validation of analytical procedures - Step 5 - Revision 1
- Guideline on manufacture of the finished dosage form
- Guideline on quality aspects included in the product information for vaccines for human use - Revision 1
- Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products
- Guideline on the development of new medicinal products for the treatment of Crohn's Disease
- Guideline on clinical investigation of recombinant and human plasma-derived factor IX products
- CHMP Reflection paper on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3
- Guideline on the quality of water for pharmaceutical use
- Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs
- Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells
While international scientific guidelines that are adopted in Australia are generally not mandated by legislation, they provide guidance to sponsors to assist them to meet the legislative requirements. Any deviation from a guideline relevant to an application to register or vary the registration of a medicine must be justified.
Enquiries
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
